Diplomat Pharmacy — Q2 2018 Earnings Presentation
16 slides from Diplomat Pharmacy's earnings presentation, Aug 6, 2018
Slide 1: Disclaimers: Non-GAAP Information
Disclaimers 2 NON-GAAP INFORMATION Adjusted non-GAAP net income and Adjusted EPS add back, net of income taxes, the impact of all merger and acquisition related expenses, including amortization of intangible assets, the change in fair value of contingent consideration, as well as transaction-related
Slide 2: Opening Remarks
Opening Remarks Brian Griffin, Chairman & CEO
Slide 3: 2Q 2018 Highlights
1 A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net (loss) income attributable to Diplomat, as prepared in accordance with GAAP can be found in the Appendix to this presentation. 2Q 2018 Highlights $1.4B (+26%) Revenue $43M (+70%) Adjusted EBITDA1 4 Solid growth in specialty and infusi
Slide 4: CastiaRx Highlights 2Q 2018
CastiaRx Highlights 5 2Q 2018 Integration almost complete $3M in 2Q synergies achieved, YTD total of $4M Now expect $8M-$10M in synergies in 2018 (vs. prior expectation of $4M-$6M) Process begun to move legacy PBM patients on LDDs to Diplomat specialty pharmacy Proposal volume remains double a year
Slide 5: Putting Patients First
Putting Patients First 6 Specialty Pharmacy Solutions PBM Manufacturer Services Infrastructure Innovation Infusion Employees The industry’s largest independent provider of specialty pharmacy services Specialty-focused PBM targeting middle market clients Nationwide provider of infusion management ser
Slide 6: Financial Results
Financial Results Atul Kavthekar, CFO
Slide 7: 2Q 2018 Financial Results
($0.05) ($4.0M) A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net (loss) income attributable to Diplomat as prepared in accordance with GAAP, can be found in the Appendix to this presentation. A reconciliation of Adjusted non-GAAP net income and Adjusted EPS, both non-GAAP measures, to
Slide 8: 2Q 2018 Segment Details
2Q 2018 Segment Details 9 Specialty PBM Revenue: $1.2B Gross margin1: 5.9% Rx volume: 236,000 Net Sales / Rx: $5,218 Gross profit / Rx1: $301 Revenue: $0.2B Gross margin: 13.7% Rx volume2: 2,123,000 Gross profit / Rx: $12 Beginning with the second quarter of 2018, certain direct expenses have been r
Slide 9: Specialty Segment Cost of Sales Reclassification
Specialty Segment Cost of Sales Reclassification In the Specialty segment, certain direct expenses (shipping & handling costs and nursing costs), that were previously classified in SG&A, are now presented in cost of sales. Changes are only a reclassification and do not impact Adjusted EBITDA, Income
Slide 10: Revised 2018 Full Year Outlook
Revised 2018 Full Year Outlook Investing for long-term growth and operational efficiency Stable margins with potential upside Deleveraging to 2-3x adjusted EBITDA in 2019 TOTAL REVENUE $5.5B - $5.9B TOTAL ADJUSTED EBITDA1 $164M - $170M 11 GAAP EPS ($0.15) - $0.01 CASH FLOW FROM OPERATIONS $115M - $1
Slide 11: Putting Patients First
Putting Patients First 12 Specialty Pharmacy Solutions PBM Manufacturer Services Infrastructure Innovation Infusion Employees JAY DIPLOMAT PATIENT
Slide 12: Appendix: Supplemental Financial Information
Appendix Supplemental Financial Information
Slide 13: Reconciliation of Net (Loss) Income to Adjusted EBITDA
Reconciliation of Net (Loss) Income Attributable to Diplomat to Adjusted EBITDA 14
Slide 14: Reconciliation of Net (Loss) Income Per Diluted Share to Adjusted EPS
Reconciliation of net (loss) income attributable to Diplomat Pharmacy, Inc. per diluted share to Adjusted EPS for the periods indicated. Please note that this will be the last time this table is provided. Going forward, Diplomat will no longer present, or provide guidance with respect to Adjusted no
Slide 15: 2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation
2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation Assumes a tax rate of (5) and 32 percent, for the low- and high-end, respectively. 16 The tables below present a reconciliation of net (loss) income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA for the year ended December 31, 201
Slide 16: 2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation
DIPLOMATA 2018 Full Year Guidance: GAAP to Non-GAAP Reconciliation ‘The tables below present a reconciliation of net (loss) income attributable to Diplomat Pharmacy, Inc. to Adjusted EBITDA forthe year ended December 31,2018 Reconciliation of 2018 GAAP to Adjusted EBITDA Guidance (olars in thousands